Collin Van Ryn

1.3k total citations
20 papers, 640 citations indexed

About

Collin Van Ryn is a scholar working on Neurology, Cancer Research and Molecular Biology. According to data from OpenAlex, Collin Van Ryn has authored 20 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Neurology, 7 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Collin Van Ryn's work include Neuroblastoma Research and Treatments (14 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer therapeutics and mechanisms (5 papers). Collin Van Ryn is often cited by papers focused on Neuroblastoma Research and Treatments (14 papers), Cancer, Hypoxia, and Metabolism (7 papers) and Cancer therapeutics and mechanisms (5 papers). Collin Van Ryn collaborates with scholars based in United States, Liberia and Switzerland. Collin Van Ryn's co-authors include Julie R. Park, Wendy B. London, Arlene Naranjo, Rochelle Bagatell, John M. Maris, Marguerite T. Parisi, Barry L. Shulkin, Paul M. Sondel, Rajen Mody and Elizabeth Fox and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Collin Van Ryn

19 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Collin Van Ryn United States 10 534 279 202 172 92 20 640
Sheena C. Tenney United States 8 501 0.9× 213 0.8× 187 0.9× 165 1.0× 67 0.7× 11 568
Valeria Smith United States 7 393 0.7× 252 0.9× 153 0.8× 117 0.7× 43 0.5× 18 531
Kristopher R. Bosse United States 12 398 0.7× 390 1.4× 229 1.1× 255 1.5× 45 0.5× 31 699
Scott C. Bresler United States 10 322 0.6× 290 1.0× 181 0.9× 237 1.4× 78 0.8× 34 603
Giovanni Erminio Italy 12 265 0.5× 156 0.6× 118 0.6× 69 0.4× 52 0.6× 20 411
Sivasish Sindiri United States 13 201 0.4× 230 0.8× 120 0.6× 276 1.6× 92 1.0× 23 661
Seeger Rc United States 14 606 1.1× 410 1.5× 214 1.1× 108 0.6× 81 0.9× 20 714
BH Kushner United States 10 381 0.7× 267 1.0× 109 0.5× 155 0.9× 56 0.6× 14 608
Stacey M. Frumm United States 7 268 0.5× 588 2.1× 123 0.6× 126 0.7× 28 0.3× 12 724
S J Yeh United States 5 296 0.6× 170 0.6× 69 0.3× 119 0.7× 44 0.5× 7 383

Countries citing papers authored by Collin Van Ryn

Since Specialization
Citations

This map shows the geographic impact of Collin Van Ryn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Collin Van Ryn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Collin Van Ryn more than expected).

Fields of papers citing papers by Collin Van Ryn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Collin Van Ryn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Collin Van Ryn. The network helps show where Collin Van Ryn may publish in the future.

Co-authorship network of co-authors of Collin Van Ryn

This figure shows the co-authorship network connecting the top 25 collaborators of Collin Van Ryn. A scholar is included among the top collaborators of Collin Van Ryn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Collin Van Ryn. Collin Van Ryn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chagomerana, Maganizo, Collin Van Ryn, Andrew Likaka, et al.. (2023). Prevalence and incidence of transfusion‐transmissible infections among blood donors in Malawi: A population‐level study. Transfusion Medicine. 33(6). 483–496. 9 indexed citations
3.
Ross, Robin D., Fred Amegashie, Bryn M. Burkholder, et al.. (2022). Long-Term Decrease in Intraocular Pressure in Survivors of Ebola Virus Disease in the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) III Study. SHILAP Revista de lepidopterología. 3(2). 100238–100238.
4.
Kelly, J. Daniel, Collin Van Ryn, Moses Badio, et al.. (2022). Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study. The Lancet Infectious Diseases. 22(8). 1163–1171. 12 indexed citations
5.
Soka, Moses J, Collin Van Ryn, Greg Grandits, et al.. (2021). The impact of the 2014 Ebola epidemic on HIV disease burden and outcomes in Liberia West Africa. PLoS ONE. 16(9). e0257049–e0257049. 3 indexed citations
6.
Braunstein, Steve, Wendy B. London, Susan G. Kreissman, et al.. (2019). Role of the extent of prophylactic regional lymph node radiotherapy on survival in high‐risk neuroblastoma: A report from the COG A3973 study. Pediatric Blood & Cancer. 66(7). e27736–e27736. 9 indexed citations
7.
Shusterman, Suzanne, Arlene Naranjo, Collin Van Ryn, et al.. (2019). Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clinical Cancer Research. 25(20). 6044–6051. 26 indexed citations
8.
Bishop, Rachel, Robin D. Ross, Jessica G. Shantha, et al.. (2019). Ebola virus persistence in aqueous humor and 12-month outcomes of cataract surgery in survivors of Ebola virus disease. 60(9). 1012–1012. 1 indexed citations
9.
Marrano, Paula, Paul S. Thorner, Arlene Naranjo, et al.. (2018). Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma. Journal of Pediatric Hematology/Oncology. 41(3). 222–227. 27 indexed citations
10.
Campbell, Kevin, Julie M. Gastier‐Foster, Arlene Naranjo, et al.. (2017). Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 123(21). 4224–4235. 95 indexed citations
11.
Mody, Rajen, Arlene Naranjo, Collin Van Ryn, et al.. (2017). Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. The Lancet Oncology. 18(7). 946–957. 182 indexed citations
12.
DuBois, Steven G., Rajen Mody, Arlene Naranjo, et al.. (2017). MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 64(11). 25 indexed citations
13.
Allmen, Daniel von, Andrew M. Davidoff, Wendy B. London, et al.. (2017). Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. Journal of Clinical Oncology. 35(2). 208–216. 91 indexed citations
14.
15.
16.
Galli, Susana, Arlene Naranjo, Collin Van Ryn, et al.. (2016). Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma. American Journal Of Pathology. 186(11). 3040–3053. 19 indexed citations
17.
18.
Kim, Grace, Erin A. Nekritz, W. Clay Gustafson, et al.. (2015). Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children’s Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging. 43(3). 474–481. 15 indexed citations
19.
Bagatell, Rochelle, Brian T. Fisher, Alix E. Seif, et al.. (2014). Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data.. Journal of Clinical Oncology. 32(15_suppl). 10069–10069. 3 indexed citations
20.
London, Wendy B., Rochelle Bagatell, Brenda J. Weigel, et al.. (2014). Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients.. Journal of Clinical Oncology. 32(15_suppl). 10034–10034. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sheena C. Tenney Breakdown of academic impact, for papers by Valeria Smith Breakdown of academic impact, for papers by Kristopher R. Bosse Breakdown of academic impact, for papers by Scott C. Bresler Breakdown of academic impact, for papers by Giovanni Erminio Breakdown of academic impact, for papers by Sivasish Sindiri Breakdown of academic impact, for papers by Seeger Rc Breakdown of academic impact, for papers by BH Kushner Breakdown of academic impact, for papers by Stacey M. Frumm Breakdown of academic impact, for papers by S J Yeh
Rankless by CCL
2026